// App-Quantinova.ai

P19.02 : Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival

Researchers

Presenter

  • Z. Wang

Principal Investigators

  • X. Han

  • J. Guo

  • D. Zhu

  • X. Zhang

  • X. Tang

Medical Centers

  • Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Cyclin Dependent Kinase Inhibitor 2A

  • Epidermal growth factor receptor

Drug/Treatment

  • Sintilimab

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved